Challenges And Opportunities Of Mrna Vaccines Against Sars Cov 2

This book offers an analytical look at the much debated risks and benefits of the newly developed COVID-19 mRNA-vaccines. As such, it is one of the first books to give a comprehensive overview of mRNA vaccines against COVID-19 and the only one that addresses this topic from a broad multidisciplinary background. It brings together insights from various underlying disciplines on the challenges of developing and evaluating the most suitable vaccines for mass vaccination programs enrolled throughout the world - focusing on safety and efficacy. This book should not be missing on the shelf of any biomedical researcher, epidemiologist, public health professional or clinical researcher interested in SARS-CoV2 or virology and vaccine development in general.

In response to the coronavirus disease 2019 (COVID-19) pandemic and the societal disruption it has brought, national governments and the international community have invested billions of dollars and immense amounts of human resources to develop a safe and effective vaccine in an unprecedented time frame. Vaccination against this novel coronavirus, severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), offers the possibility of significantly reducing severe morbidity and mortality and transmission when deployed alongside other public health strategies and improved therapies. Health equity is intertwined with the impact of COVID-19 and there are certain populations that are at increased risk of severe illness or death from COVID-19. In the United States and worldwide, the pandemic is having a disproportionate impact on people who are already disadvantaged by virtue of their race and ethnicity, age, health status, residence, occupation, socioeconomic condition, or other contributing factors. Framework for Equitable Allocation of COVID-19 Vaccine offers an overarching framework for vaccine allocation to assist policy makers in the domestic and global health communities. Built on widely accepted foundational principles and recognizing the distinctive characteristics of COVID-19, this report's recommendations address the commitments needed to implement equitable allocation policies for COVID-19 vaccine.

Dr. Jose Luis Subiza is the founder and CEO of Inmunotek SL. The other Topic Editors declare no competing interests with regard to the Research Topic subject.

In A Shot in the Arm, MIT Professor Yossi Sheffi recounts the extraordinary journey to deliver Covid-19 vaccines: from scientific advancements to candidate vaccines and mass vaccination. It is a story of bold innovation, risk-taking, and teamwork as scientists, engineers, supply chain experts, manufacturers, and governments collaborated on the greatest product launch in history. The book also highlights the breathtaking potential of revolutionary mRNA technology and the vital lessons for combating other global challenges, including climate change.

This volume presents detailed laboratory protocols for in vitro synthesis of mRNA with favorable properties, its introduction into cells by a variety of techniques, and the measurement of physiological and clinical consequences such as protein replacement and cancer immunotherapy. Synthetic techniques are described for structural features in mRNA that provide investigational tools such as fluorescence emission, click chemistry, photo-chemical crosslinking, and that produce mRNA with increased stability in the cell, increased translational efficiency, and reduced activation of the innate immune response. Protocols are described for clinical applications such as large-scale transfection of dendritic cells, production of GMP-grade mRNA, redirecting T cell specificity, and use of molecular adjuvants for RNA vaccines. Written in the highly successful Methods in Molecular Biology series format, chapters include introductions to their respective topics, lists of the necessary materials and reagents, step-by-step laboratory protocols, and tips on troubleshooting and avoiding known pitfalls. Synthetic mRNA: Production, Introduction into Cells, and Physiological Consequences is a valuable and cutting-edge resource for both laboratory investigators and clinicians interested in this powerful and rapidly evolving technology.

The severe acute respiratory syndrome virus (SARS) first emerged in southern China in November 2002 and in the following months spread to 12 other countries in the Western Pacific region (where 95 per cent of the global cases took place) with devastating force. By July 2004, when the epidemic was finally declared over, it had killed nearly 800 people including many healthcare workers. Although by some standards, this first emerging and readily transmissible disease of the 21st century was not a big killer, it caused more fear and social disruption than any other outbreak of our time. Written largely by the public health experts and scientists involved in efforts to control the epidemic, this publication examines the emergence and spread of SARS, the public health measures taken to deal with it, the epidemiology of the SARS coronavirus (SAR-CoV) and vaccine development, and its impact on people and economies in individual countries, in the region and around the world.

The seventh edition of the Canadian Immunization Guide was developed by the National Advisory Committee on Immunization (NACI), with the support ofthe Immunization and Respiratory Infections Division, Public Health Agency of Canada, to provide updated information and recommendations on the use of vaccines in Canada. The Public Health Agency of Canada conducted a survey in 2004, which confi rmed that the Canadian Immunization Guide is a very useful and reliable resource of information on immunization.